BAXTER INTERNATIONAL INC acquired North American Vaccine, Inc. for $328M, a transaction completed in June 2000, structured as Acquisition principally settled with approximately 3,770,000 shares of Baxter common stock.
North American Vaccine, Inc. operates in BioScience, is based in Columbia, Maryland, United States. Baxter acquired North American Vaccine, Inc. (NAV), a Columbia, Maryland company engaged in the research, development, production and sale of vaccines for the prevention of human infectious diseases. The deal broadened Baxter's position in the global vaccines market and added programs such as the NeisVac-C meningococcal vaccine.
Broadened Baxter's global vaccines pipeline and market position, adding meningococcal and other vaccine programs.
Advisory firms were not disclosed for this transaction.